Key result
Andexanet alfa was associated with a higher rate of substantial intracranial hemorrhage growth compared to 4F-PCC.
Why the study?
While guidelines recommend andexanet alfa for reversing factor Xa inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate despite limited comparative data.
Does andexanet alfa reduce clinically significant intracranial hemorrhage expansion compared to 4-factor prothrombin complex concentrate in patients with factor Xa inhibitor-associated acute intracranial hemorrhage?
Cohort (n=134)
No
Does andexanet alfa reduce clinically significant intracranial hemorrhage expansion compared to 4-factor prothrombin complex concentrate in patients with factor Xa inhibitor-associated acute intracranial hemorrhage?
Answers are grounded in this paper and cite their sources.
In real-world practice predominantly involving traumatic intracranial bleeds, 4F-PCC achieved comparable clinical outcomes and lower unadjusted rates of substantial hematoma expansion compared to andexanet alfa, supporting 4F-PCC as a viable reversal alternative.
Background While guidelines recommend andexanet alfa (AA) for reversing factor Xa (FXa) inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate (4F-PCC), despite limited comparative data. This comparative effectiveness study evaluates AA vs. 4F-PCC for bleeding control in clinical practice. Methods We conducted a retrospective review of patients with acute intracranial hemorrhage who were on a factor Xa inhibitor and received 4F-PCC or AA. Demographics, clinical severity, hemorrhage volume, treatment timing, and discharge outcomes were compared. Primary outcomes were absolute and percent hemorrhage volume change, substantial hemorrhage growth (> 6 mL or >33%), and neurological deterioration (≥ 2-point GCS decrease or ≥4-point NIHSS increase). Data were analyzed using Wilcoxon Rank Sum, chi-squared tests, and Kaplan–Meier curves. Results Among 132 eligible patients, 43 received AA and 89 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Mean age was 78 years, and average baseline hemorrhage volume was 37 mL. Age, gender, race, and door-to-needle times did not differ between groups. AA patients had higher NIHSS (9 vs. 5, p = 0.003) and lower GCS (12 vs. 13, p = 0.03) scores on admission. Mean absolute and percent hemorrhage volume changes were similar; however, more patients on AA had substantial hemorrhage growth (43% vs. 22%, OR=2.65, p = 0.02). After adjustment for covariates, the association between AA and substantial hemorrhage expansion narrowly missed statistical significance (adjusted OR 2.29, P = 0.08). Neurological deterioration rates and thromboembolic complications were comparable. Conclusions AA was linked to a numerically higher risk of substantial intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, and mortality. 4F-PCC may serve as a viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.
No takes yet. Share an insight, caveat, or question.
Rajpal et al. (2026) conducted a cohort in Factor Xa inhibitor-associated acute intracranial hemorrhage (n=134). Andexanet alfa vs. 4-factor prothrombin complex concentrate (4F-PCC, recommended 50 units/kg) was evaluated on Clinically significant intracranial hemorrhage expansion (absolute increase in volume of >=6 mL or >=33% relative increase from baseline) (OR 2.65, p=0.02). Andexanet alfa was associated with a higher rate of substantial intracranial hemorrhage growth compared to 4F-PCC.
Synapse has enriched 10 related papers. Consider them for comparative context: